The collaboration aims to integrate these algorithms into routine eye examinations, facilitating the diagnosis of CKD.

Tempus AI stock is trading at a nosebleed valuation, and despite the compelling long-term upside, it's not worth investing at ...

Tempus AI continued to see dramatic revenue and gross profit growth in the first quarter, with year-over-year revenue up 75.4% and quarterly gross profit nearly doubling, the Chicago-based health care ...

AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.

Tempus AI, Inc. is revolutionizing healthcare genomics with AI and data partnerships. Click here to read an analysis on TEM ...

Tempus AI Inc. TEM during the first quarter secured ... a substantial portion of the computing costs will be covered by AstraZeneca and Pathos AI. Lefkofsky says that the model is expected to ...

Despite a turbulent 2025, Ark Invest CEO Cathie Wood is currently sitting on a big win with her investment in Tempus AI ...

From surgical precision tools to real-time diagnostics, brain-responsive stimulation, and multi-disease detection systems, AI ...

In other news, Tempus AI Inc. (NASDAQ:TEM) clinched a new $200-million deal with AstraZeneca and Pathos AI for the development of a multimodal foundation model in oncology. The total amount ...

Stocks recently featured in the blog include: Tempus AI TEM, AstraZeneca AZN, iRhythm Technologies IRTC and SOPHiA GENETICS SOPH. Here are highlights from Thursday’s Analyst Blog: Tempus AI ...